Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very clean, only $24,639 in current liabilities
Saw that. The fact that this institution has been buying very large amounts over the past week is one of the more encouraging signs from ENDV that I’ve witnessed. It’s certainly caused me to take notice.
Wall Street Access Asset Management is based out of New York. Wall Street Access Asset Management is a hedge fund with More than 100 clients and discretionary assets under management (AUM) of $295,046,586 (Form ADV from 2016-09-01). Their last reported 13F filing for Q1 2018 included $73,406,000 in managed 13F securities and a top 10 holdings concentration of 50.27%. Wall Street Access Asset Management's largest holding is iShares Trust - Core S&P 500 Exchange Traded Fund with shares held of 29,464. Whalewisdom has at least 31 13F filings
WABR information...
Since 1981, Wall Street Access has adopted an independent, entrepreneurial culture to build and operate a diverse set of successful financial services businesses. From execution services, fixed income and securities research to wealth management, our firm has the expertise, depth, flexibility and capital to quickly seize emerging opportunities. Wall Street Access has successfully evolved through many market cycles while always remaining a trusted and reliable partner for our clients.
I’m starting to believe you are correct now...
100k sells not moving WABR...
With 14,739,627 shares outstanding I agree
The Company is currently in negotiation to enter into an unrelated line of business through the acquisition of a private company with ongoing operations. Finalization of said business combination is anticipated to close on or before June 1, 2018.
Exactly, pretty sure we haven’t
$ENDV looking as solid as I have seen in a very long time...
DCLT .0029 crazy down here. Real business with revenues and 145 million OS...NO toxic notes. Zero
DCLT .0029 200 million AS, $88k of total debt and coming off a huge conference in Las Vegas.
HVCW .0004 cash flow positive from last PR. Lots of 4’s loaded down here
HVCW been loading 4’s. We shall see
You can say that again!
Very well possible. Might see more news with the current rate.
$SRUP
That it is!
$SRUP thinning out nicely now
Yeah, hope you are well. It’s been quite a long process but appears to be coming to a head soon. Nice to see some posts and attention here again.
$TVOG
The company is very much in business and doing very well I believe.
$DCLT
Again, only speculation as I stated. I am active on Twitter and part of Primestar board where IR posts occasionally. I have conversed with both Steve Helm and the former IR representative in the past though.
Sorry for just now getting back. Thank you for the kind words.
Obviously don’t think we will see a PR today but perhaps a filing after hours, only speculation though. I do believe we see filings and news next week. Management is making sure all the t’s are crossed before releasing the kraken in my opinion. Especially after the small form 10 setback. Once the process starts, it should be a long string of very positive events going forward.
Good morning group! Good news attorney letter was posted this morning. Management said there was some confusion due to a date change by OTC and they didn’t notify the Company. Any yield should be remedied ASAP. Now management says they are ready for news! Here is link: https://backend.otcmarkets.com/otcapi/company/financial-report/192429/content $TVOG IR
AWON .002 up. Slowly moving up. Nice chart...
19’s gone early...
ENDV .032 mentioned with 4 Nasdaq companies...
The Nasdaq Biotechnology Index has is approximately 25% off of its all time high from back in July of 2015. With all of the incredible breakthroughs in biotechnology over the last few years, it is a very exciting time for those involved in biotech companies.
On the heels of CVS Health's (CVS) big announcement that it plans to focus on kidney care and dialysis to improve patient outcomes and reduce costs, some other biotechnology companies that have made major announcements recently include: Endonovo Therapeutics, Inc. (OTC:ENDV), Heat Biologics, Inc. (NASDAQ: HTBX), Neovasc, Inc. (NASDAQ: NVCN), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Akers Biosciences, Inc. (NASDAQ: AKER)
Endonovo Therapeutics, Inc. (QTCQB: ENDV)
Market Cap: $10.5M, current share price: $0.031
ENDV, a commercial stage developer of wearable non-invasive Electroceutical™ therapies targeting post-operative pain and edema, chronic wounds, cardiovascular disease, renal disease and central nervous system disorders, recently highlighted positive results from an early feasibility study of its Electroceutical™ Therapy in reducing Proteinuria in 4 patients with chronic kidney disease (CKD). The Company is now planning to conduct a larger clinical trial in CKD.
The Company's Electroceutical™ therapy, SofPulse™, is an easy-to-place, non-invasive device that delivers targeted MicroCurrent Therapy (tMCT) to enhance post-surgical recovery. The Company's non-invasive Electroceutical™ therapy using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. ENDV recently stated that it is pursuing several sales and distribution channels in its 10-k annual report. The Company's strategy for commercialization centers on establishing SofPulse™ as standard care for post-surgical healing for the more than 850,000 cosmetic procedures performed each year in the US. Additionally, ENDV is establishing sales and distribution channels to target the Veteran's Affairs medical facilities and the more than 15,000 skilled nursing facilities in the United States.
ENDV .032 mentioned with 4 Nasdaq companies...
The Nasdaq Biotechnology Index has is approximately 25% off of its all time high from back in July of 2015. With all of the incredible breakthroughs in biotechnology over the last few years, it is a very exciting time for those involved in biotech companies.
On the heels of CVS Health's (CVS) big announcement that it plans to focus on kidney care and dialysis to improve patient outcomes and reduce costs, some other biotechnology companies that have made major announcements recently include: Endonovo Therapeutics, Inc. (OTC:ENDV), Heat Biologics, Inc. (NASDAQ: HTBX), Neovasc, Inc. (NASDAQ: NVCN), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Akers Biosciences, Inc. (NASDAQ: AKER)
Endonovo Therapeutics, Inc. (QTCQB: ENDV)
Market Cap: $10.5M, current share price: $0.031
ENDV, a commercial stage developer of wearable non-invasive Electroceutical™ therapies targeting post-operative pain and edema, chronic wounds, cardiovascular disease, renal disease and central nervous system disorders, recently highlighted positive results from an early feasibility study of its Electroceutical™ Therapy in reducing Proteinuria in 4 patients with chronic kidney disease (CKD). The Company is now planning to conduct a larger clinical trial in CKD.
The Company's Electroceutical™ therapy, SofPulse™, is an easy-to-place, non-invasive device that delivers targeted MicroCurrent Therapy (tMCT) to enhance post-surgical recovery. The Company's non-invasive Electroceutical™ therapy using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. ENDV recently stated that it is pursuing several sales and distribution channels in its 10-k annual report. The Company's strategy for commercialization centers on establishing SofPulse™ as standard care for post-surgical healing for the more than 850,000 cosmetic procedures performed each year in the US. Additionally, ENDV is establishing sales and distribution channels to target the Veteran's Affairs medical facilities and the more than 15,000 skilled nursing facilities in the United States.
TVOG .0265 almost time...
Initial Bitumen Tanker Acquisitions are Projected to Generate $39,000,000 in Annual Revenue and $6,000,000 EBITDA.
Initial Bitumen Tanker Acquisitions are Projected to Generate $39,000,000 in Annual Revenue and $6,000,000 EBITDA.
Look at the rate of news over the past 2 months. This company is gearing up for a major market takeover imo. Things are accelerating at a very fast pace. The market will catch on very soon I believe.
$SRUP
Sparrow Marcioni, Sirrus Corp. CEO, commented, “With a solid team of experienced technology sales and marketing professionals now in place, we are strongly positioned to execute an expanded strategy to build awareness of our proven cybersecurity services and develop new business.”
Sirrus Corp. expects that the expanded marketing efforts will provide significant additional exposure for its established cybersecurity penetration testing business and also highlight the Company’s recently established high-performance computer (HPC) and security passkey divisions.
The Company anticipates releasing additional information regarding new business development as the sales and marketing strategy progresses.
With a cost in excess of $50,000 per device, the entry level Sirrus Secure HPC is built to deliver an extraordinary amount of processing power fueled by 64 separate computing cores running proprietary software based on the Linux operating system with enhanced network security. By combining several proprietary and non-proprietary design and build techniques into the Sirrus Secure HPC, just one unit has the capability to replace an entire rack of legacy servers and close hundreds of potential security gaps. As a result, the total cost to operate and maintain a Sirrus Secure HPC has been shown to be greatly reduced compared to traditional systems of this capacity.
Marcioni concluded, “Our in-house expertise with every aspect of cybersecurity and also cutting-edge system architecture has positioned Sirrus to potentially become a market leader for security focused custom built high-performance computer systems. We look forward to working with potential new clients in several rapidly expanding market segments we have identified.”
This sale commenced during the previous fiscal quarter and the Company expects to deliver the Secure HPC system to the customer within the next week.
Agreed!!!
Fantastic avatar if I hadn’t already said so...
I feel so, almost grabbed those 32’s end of day but will plan on it tomorrow. Company has been extremely active as of late and I don’t see that changing anytime soon. Should see a follow up to yesterday’s PR with more contracts and more revenues soon.
$SRUP
You bet and $TVOG is gearing up as we speak...
https://primestarbitumen.com/cargo-chartering/
I like the way this ones trading now. Only a matter of time imho...
$SRUP